IOVANCE BIOTHERAPEUTICS, INC. |
Director |
Deferred Restricted Stock Unit |
98.6K |
$825K |
$8.37 |
Jun 11, 2024 |
Direct |
IOVANCE BIOTHERAPEUTICS, INC. |
Director |
Common Stock |
54K |
$494K |
$9.15 |
Feb 20, 2024 |
Direct |
Traws Pharma, Inc. |
Executive Chairman, Director |
Common Stock |
134K |
$63.1K |
$0.47 |
Apr 1, 2024 |
Direct |
Theseus Pharmaceuticals, Inc. |
Director |
Common Stock |
0 |
$0 |
$3.05 |
Feb 14, 2024 |
Direct |
Theseus Pharmaceuticals, Inc. |
Director |
Restricted Stock Units |
0 |
$0 |
$3.05 |
Feb 14, 2024 |
Direct |
Onconova Therapeutics, Inc. |
Executive Chairman, Director |
Stock Option (right to purchase) |
3.8M |
|
|
Apr 1, 2024 |
Direct |
Venetian-1 Acquisition Corp. |
CEO and Chairman, Director |
Stock Option (Right to Buy) |
2.1M |
|
|
Nov 1, 2024 |
Direct |
Ikena Oncology, Inc. |
Director |
Stock Option (Right to Buy) |
17.5K |
|
|
Jun 7, 2024 |
Direct |
Onconova Therapeutics, Inc. |
Executive Chairman, Director |
Series C Preferred Stock |
4.8K |
|
|
Apr 1, 2024 |
By Viriom, Inc. |
Onconova Therapeutics, Inc. |
Executive Chairman, Director |
Series C Preferred Stock |
195 |
|
|
Apr 1, 2024 |
Direct |
Theseus Pharmaceuticals, Inc. |
Director |
Stock Option (Right to Buy) |
0 |
|
|
Feb 14, 2024 |
Direct |